Purchase Order 75N95023P00469
Award Date
7/25/23
Potential Completion Date
7/24/24
Potential Value
$288K
Federal Agency
National Institute on Drug Abuse
Awardee
Curia Global Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $1,297,587.74 cost-plus-fixed-fee delivery order to Curia Global Inc. (doing business as Amri) for the Medicinal Chemistry Support Program for Therapeutic Development. This program supports medicinal chemistry and other drug discovery and development services to advance treatments for conditions such as Alzheimer's disease, Parkinson's disease, pain, substance abuse, and...
This federal contract award to Curia Global Inc., doing business as Amri, is for the production of non-GMP (non-Good Manufacturing Practice) batches of the drug substances paynantheine, speciogynine, and speciociliatine salts. The contract, valued at $1,259,570.66, was awarded under the National Institute on Drug Abuse's (NIDA) indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for Contract Research Organization (CRO) Support for NCATS Drug Substance Development and Manufacture....
This is a $3,453,835.19 delivery order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) to Curia Global Inc., doing business as Amri, a for-profit manufacturer. The contract is for the Medicinal Chemistry Support Program for Therapeutic Development, which provides chemistry, manufacturing, and controls development; exploratory chemistry; hit-to-lead chemistry;...
This is a federal delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit manufacturer. The $160,419.00 cost-plus-fixed-fee contract is part of NIDA's Drug Manufacturing and Formulation Program (DMFP) Indefinite Delivery, Indefinite Quantity (IDIQ) master contract and has a period of performance through June 4, 2025. The contract does not have a small business set-aside designation. Curia...
This is a $1,485,008.40 non-competitive firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA) to Curia Global Inc., a for-profit pharmaceutical manufacturing and research company. The contract supports a 12-month base period with four 12-month option periods to synthesize up to 100 compounds under non-GMP conditions for a medicinal chemistry discovery program aimed at identifying molecules that bind the KIAA0203 protein, which could potentially lead to the...
This is a delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit manufacturer, under the Drug Manufacturing and Formulation Program (DMFP) indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The $725,724.21 cost-plus-fixed-fee contract has an ultimate completion date of June 30, 2021 and does not have a set-aside designation. Curia, a leading global contract development and manufacturing...
This is a delivery order award to Curia Global Inc., doing business as Amri, under the Drug Manufacturing and Formulation Program (DMFP) IDIQ contract with the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services. The $219,167.73 cost-plus-fixed-fee award has a performance period through September 24, 2024 and does not include a set-aside designation. Curia, a leading global contract development and manufacturing organization, will provide...
This is a delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit manufacturer. The contract is part of the larger Drug Manufacturing and Formulation Program (DMFP) Indefinite Delivery, Indefinite Quantity (IDIQ) master contract vehicle. The award is for $1,135,799.54 and covers feasibility studies, clinical trial readiness activities, and good manufacturing practice (GMP)/clinical trial...
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $3,173,498.83 cost-plus-fixed-fee Delivery Order contract to Curia Global Inc., doing business as Amri, for Exploratory Chemistry services under the Medicinal Chemistry Support Program for Therapeutic Development. The contract has a completion date of February 1, 2026 and does not have a small business set-aside designation. Curia, a global contract...
This federal contract task order was awarded by the U.S. Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to Curia Global Inc., doing business as Amri, a leading global contract development and manufacturing organization (CDMO). The $1,376,049.53 cost-plus-fixed-fee task order, awarded on August 15, 2018, supports the Medicinal Chemistry Support Program for Therapeutic Development, providing chemistry, manufacturing, and controls...